Mohammad Keykhaei, MD, MPH

PGY-1 IM Resident @DOM_UCLA| Former Postdoc @HopkinsHeart| Editorial Board @BMC_GPH, @FrontCVMedicine|🏊✈️🎹📚

[Mohammad Keykhaei, MD, MPH @MKeykhaeiMD]

1/🚨Excited to share our new study published in @JAMACardio:

“Cost Offset With Quadruple Therapy for Heart Failure”

https://t.co/QLns4LXvSc

Deeply grateful to Dr. @gcfmd and our amazing team for their unwavering support and mentorship:
@SinaRsh @SJGreene_md @NMHheartdoc @boback @ATSandhu @MKittlesonMD
@uclaCVfellows @DOM_UCLA @uclaimchiefs @UCLAHealth @dgsomucla
#HeartFailure #HFrEF #GDMT

[Michelle Kittleson MD PhD @MKIttlesonMD]

I have NO clear plan on how to optimally incorporate AI in patient care-- but there are times when AI isn't enough.

And don't forget to sign up for email alerts so you never miss a piece- no subscription to @NEJM required- access is free!

https://t.co/yofU2PzT9N

[Gregg Fonarow MD @gcfmd]

Heart Failure: New Definition Will Improve Diagnosis, Transform Care

https://t.co/17ohIP8jAj via @healthline

@UCLAHealth @UCLAHealthNews @DOM_UCLA @ACCinTouch @American_Heart @HFSA

[Eric H Yang, MD @datsunian]

Indeed it was great seeing Warren's defense--amazing culmination of basic science, being a 🔥 clinician, @uclaCVfellows #bruinhearts chief fellow & now future IC fellow. Congrats Warren!
Many 🙏 to STAR leadership, @IntMedAbel @kewatson @CardioOncology 4 your support of his path!

[Xinjiang Cai, MD, PhD 🫀 @XinjiangCai]

It’s wonderful to attend Warren Tai’s thesis defense today.

Warren joined our UCLA Cardiology Fellowship @dgsomucla STAR program via Vanderbilt (@CardioOncology). Now he has completed his PhD studies on cardiac metabolism in the @IntMedAbel lab.

Congrats, Warren!

[Gregg Fonarow MD @gcfmd]

🫀💔 How many US individuals with heart failure ☠️ each year?

📋 90,000: HF as the UNDERLYING cause

🩺 418,000: HF anywhere on the death cert (~1 in 7 U.S. deaths!) 😳

🧪 ~328,000: 7.7M patients × volunteer-cohort death rate

🌎 ~810K–1M : 7.7M × population-based death rate

[Gregg Fonarow MD @gcfmd]

🫀 The price tag of HF in the US is staggering

💵 $39,470/year per patient (2025 dollars), nearly 5× the cost for adults without HF

🏥 40% goes to hospitalization alone

📈 7.7M Americans affected

💸 $304 BILLION in annual spending

🆘 HF = clinical and economic crisis

[Eric H Yang, MD @datsunian]

A 🔥 intro to our 2026-27 new @uclahealth @uclaCVfellows chief fellows!

@kinan_bachour @BiancaLavelle @repettigiuliana #torispeck

We are thrilled to have our new class of leaders inspire the next gen of our #bruinhearts & continue to evolve our fellowship to the next level!

[Gregg Fonarow MD @gcfmd]

Registration is now open

[Ahmed Bennis MD 🫀 @drbennisahmed]

🧵 ICI rechallenge after immune checkpoint inhibitor myocarditis

1️⃣ Is restart justified? Weigh tumor benefit vs. available non-ICI alternatives; ensure patient understands the uncertainty

2️⃣ Is the patient ready? No unstable HF/arrhythmia, no active myositis

[Giuliana Repetti @repettigiuliana]

New review in @CircRes! GLP-1R agonists are more than weight loss drugs — we explore how they reshape lipoprotein metabolism & adipose tissue to reduce CV risk beyond adiposity.

https://t.co/nVlfgXPboF

#GLP1 #Cardiology #Lipids

[Department of Medicine at UCLA Health @DOM_UCLA]

Congratulations to the UCLA STAR Program graduates! These outstanding physician-scientists have made a significant impact during their time at UCLA and are advancing medicine through research, mentorship and innovation. Learn about their achievements: https://t.co/YzovEV3VJM

[Mohammad Keykhaei, MD, MPH @MKeykhaeiMD]

🚨Our study in @JAMACardio was featured by TCTMD.
Key finding:
✅ Quadruple GDMT for HFrEF was projected to reduce HF hospitalizations by 87%
✅ Reduce all-cause hospitalizations by 61%
✅ Lower hospitalization-related costs by nearly $10,000 per patient-year
✅ As drug costs continue to decline with generic availability, the value proposition of GDMT becomes even more compelling.
📰 Read the TCTMD feature:
https://t.co/QKphYIbusN

@gcfmd @NMHheartdoc @SJGreene_md @boback @MKIttlesonMD @ATSandhu @DOM_UCLA @uclaCVfellows @uclaimchiefs

[Gregg Fonarow MD @gcfmd]

For HFrEF, Quadruple Therapy Lowers Costs Mostly by Reducing Hospitalizations https://t.co/popwslSqLM

@UCLAHealthNews @JAMACardio @NMHheartdoc @MKeykhaeiMD @ATSandhu @MKIttlesonMD @SJGreene_md @boback @TCTMD

[Eric H Yang, MD @datsunian]

Another 🔥 #bruinhearts @uclaCVfellows class 👩‍🎓 👨‍🎓, ready to make their mark on the world

🙏 to PD leaders @kewatson @netta_doc @arafiqmd1 #armandomartinez & our amazing Chiefs

🥳 to @PeterHannaMD (Mentor of year) & #srikrishnan (Teacher of year) 4 your passion & dedication!

[Tariq Ahmad MD MPH @yaleHFdoc]

Congrats to @JACCJournals #JACCHF for being the #1 heart failure journal under the incredible leadership of @BiykemB

[Roger Blumenthal @rblument1]

New cholesterol guidelines push plant-forward diets, but US meat myths persist https://t.co/gi9IeF4GJj - Excellent quotes by @lenoxhill @WellSpan Prevention guru @ devoted @Yankees & @Knicks fan with Mariska & Taylor @EugeniaGianos @DrEugeneYang @ACCinTouch

[Gregg Fonarow MD @gcfmd]

These findings potentially support expanding GLP1-RA use to broader cardiometabolic prevention, though long-term data in healthy weight and lower-risk populations are warranted

[UCLA Cardiology Fellowship @uclaCVfellows]

@MCalfonPressMD Endless gratitude to Dr. Press for her generosity and graciousness to host both our Women in Cardiology and the Interventional Cardiology Journal Clubs at her home this year. Thank you for fostering such rich discussion on the trials shaping our field! #WIC #UCLAhealth #IC #MedEd #Cardiology

[JAMA Cardiology @JAMACardio]

Quadruple guideline-directed medical therapy in #HeartFailure with reduced ejection fraction was projected to offset hospitalization costs by nearly $10 000 per patient-year, frequently yielding net health care savings.

https://t.co/xLbcUJUBgy

[Gregg Fonarow MD @gcfmd]

Cardiovascular outcomes of glucagon-like peptide-1 receptor agonists in patients without obesity: a systematic review and meta-analysis of randomized controlled trials

GLP1-RAs reduce MACE and CV death in individuals irrespective of the obesity status

https://t.co/UVtpiERw54